Gafencu Dumitrita Alina, Welter Stefan, Cheufou Danjouma Housmanou, Ploenes Till, Stamatis Georgios, Stuschke Martin, Theegarten Dirk, Taube Christian, Bauer Sebastian, Aigner Clemens
Department of Thoracic Surgery, University Medicine Essen, Ruhrlandclinic, Essen, Germany.
Department of Thoracic Surgery, Lung Clinic Hemer, Hemer, Germany.
J Thorac Dis. 2017 Oct;9(Suppl 12):S1278-S1281. doi: 10.21037/jtd.2017.07.47.
Pulmonary metastasectomy is an established treatment modality for patients with soft as well as bone tissue sarcomas. Aim of this study is to describe the Essen experience in the surgical management of patients with pulmonary sarcoma metastases.
This is a retrospective single center analysis of perioperative outcome of patients undergoing pulmonary metastasectomy for sarcoma metastases from 1997-2017 and a summary of published papers on this topic.
During the observation period 327 patients (49.23% female) underwent pulmonary metastasectomy for metastases of extrathoracic sarcomas in curative intent. The number of resected metastases was 1-3 in 283 cases (86.54%), 4-9 in 31 cases (9.48%) and 10 or more lesions in 14 cases (4.28%). Wedge resections or precision excisions with laser or electrocautery were performed in 278 cases (85.02%), anatomical segmental resections in 16 patients (4.89%) and lobectomies in 33 patients (10.09%). Bilateral procedures were performed in 98 cases (29.96%). Lymphadenectomy was performed in 122 patients. Positive lymph nodes were found only in 6 cases. All of these cases were patients with soft tissue sarcoma as primary tumor. Preoperative neoadjuvant treatment was performed in 79 patients (24.15%) with chemotherapy, in 54 patients (16.51%) with radiochemotherapy and in 10 patients (3.05%) with radiotherapy. Major postoperative complications were observed in 2.75% of all patients. Thirty-day mortality was 0%.
Pulmonary metastasectomy in sarcoma patients is a feasible and safe treatment strategy even in patients with bilateral metastases and multiple lesions. Thoracic lymph node metastases are rare and did not influence survival in our cohort.
肺转移瘤切除术是软组织肉瘤和骨肉瘤患者公认的治疗方式。本研究旨在描述埃森在肺肉瘤转移患者外科治疗方面的经验。
这是一项对1997年至2017年因肉瘤转移接受肺转移瘤切除术患者围手术期结果的回顾性单中心分析,以及关于该主题已发表论文的总结。
在观察期内,327例患者(49.23%为女性)出于根治目的接受了肺转移瘤切除术,以切除胸外肉瘤的转移灶。283例(86.54%)患者切除的转移灶数量为1至3个,31例(9.48%)为4至9个,14例(4.28%)为10个或更多。278例(85.02%)患者接受了楔形切除术或使用激光或电灼进行的精确切除术,16例(4.89%)患者接受了解剖性肺段切除术,33例(10.09%)患者接受了肺叶切除术。98例(29.96%)患者进行了双侧手术。122例患者进行了淋巴结清扫术。仅6例患者发现阳性淋巴结。所有这些病例均以软组织肉瘤为原发肿瘤。79例(24.15%)患者术前接受了化疗新辅助治疗,54例(16.51%)患者接受了放化疗新辅助治疗,10例(3.05%)患者接受了放疗新辅助治疗。所有患者中2.75%出现了主要术后并发症。30天死亡率为0%。
肉瘤患者的肺转移瘤切除术是一种可行且安全的治疗策略,即使是双侧转移和多发病灶的患者。胸段淋巴结转移罕见,在我们的队列中不影响生存。